NASDAQ:PBLS Parabilis Medicines Q2 2026 Earnings Report $35.53 -1.88 (-5.03%) As of 03:27 PM Eastern ProfileEarnings HistoryForecast Parabilis Medicines EPS ResultsActual EPS-$2.32Consensus EPS -$0.16Beat/MissMissed by -$2.16One Year Ago EPSN/AParabilis Medicines Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AParabilis Medicines Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Parabilis Medicines Earnings HeadlinesParabilis Medicines: Q2 Earnings SnapshotAugust 13 at 9:30 AM | finance.yahoo.comParabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 13 at 7:00 AM | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 13 at 1:00 AM | Altimetry (Ad)This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayJuly 6, 2026 | benzinga.comPBLS Parabilis Medicines, Inc.July 2, 2026 | seekingalpha.comThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already InvestedJune 27, 2026 | fool.comSee More Parabilis Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Parabilis Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Parabilis Medicines and other key companies, straight to your email. Email Address About Parabilis MedicinesParabilis Medicines (NASDAQ:PBLS) Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.View Parabilis Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?SpaceX’s First Earnings Report Only Made Wall Street More DividedFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandLumentum Just Delivered the AI Growth Investors WantedCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit Test Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
